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Abstract
Introduction: There are currently no guidelines for switching patients from oral risperidone to paliperidone
palmitate (Invega SustennaW). Furthermore, the paliperidone long-acting injectable (LAI) package insert
does not recommend bridging with oral antipsychotics, which may result in inadequate serum
concentrations in patients on 4 mg/d risperidone.
Methods: This study evaluated the effects of suboptimal dosing and bridging in patients switched from oral
risperidone to paliperidone LAI on hospitalization days, emergency department (ED)/mental health urgent
care visits, and no-shows/cancellations to mental health appointments. Patients were categorized into
optimal or suboptimal dosing based on their loading and maintenance paliperidone doses. Patients on
risperidone 4 mg/d were categorized as bridged if they received risperidone for 7 days after the first
paliperidone injection.
Results: There were no significant differences in outcomes between optimally and suboptimally dosed
patients. There were statistically significant reductions in hospitalization days in patients who were bridged
compared with patients who were not bridged. There were statistically significant reductions in
hospitalization days and ED/mental health urgent care visits after switching to paliperidone LAI.
Discussion: The results of this study indicate that bridging patients who are on 4 mg/d risperidone, when
converting to paliperidone LAI, is associated with reductions in hospitalization days. However, more research
is required to determine the optimal dose and duration of the bridge. The results also indicate that
switching patients from oral risperidone to paliperidone LAI, even if the dose is suboptimal, is associated
with reductions in hospitalization days and ED/mental health urgent care visits.
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Introduction
Studies have demonstrated that patients with schizophre-
nia started on the long-acting injectable (LAI) paliperidone
palmitate (Invega SustennaW, Janssen Pharmaceutical
Titusville, NJ) have improved adherence, reduction in
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permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
rehospitalizations, and prolonged time to relapse com-
pared with patients on typical and atypical oral antipsy-
chotics.1-3 These studies also note that dose adjustments
in paliperidone LAI maintenance doses are often required
because of incomplete efficacy.4-6 There are limited
guidelines for switching patients from oral antipsychotics
to paliperidone LAI. The primary guidance comes from the
paliperidone LAI package insert, which provides equiva-
lencies for paliperidone extended-release (ER) tablets and
paliperidone LAI.7 At the Veterans Affairs San Diego
Healthcare System (VASDHS) and other institutions,
risperidone is the most commonly prescribed oral
antipsychotic before patients are switched to paliperidone
LAI, because it is inexpensive.8 Additionally, paliperidone
LAI is preferred over risperidone LAI because it is dosed
monthly (risperidone LAI is every 2 weeks) and does not
require refrigeration.7 Although patients are often
switched from oral risperidone to paliperidone LAI, there
are no published studies recommending or evaluating a
conversion between the two.4,7,8
The paliperidone LAI package insert recommends loading
doses that result in plasma concentrations approximately
equivalent to those of 6 to 12 mg of oral paliperidone ER.7
The package insert also states bridging with oral
antipsychotics is not necessary. However, because 4
mg/d oral risperidone is approximately equivalent to 8
mg/d paliperidone ER, recommended loading doses of
paliperidone LAI would yield concentrations approximate-
ly equivalent to 3 to 6 mg of oral risperidone.9 Especially if
the plasma concentrations are closer to 6 mg of
paliperidone ER (3 mg of oral risperidone), this may lead
to subtherapeutic concentrations in patients who require
doses of oral risperidone 4 mg/d.
The objectives of this study were to evaluate the effects of
optimal dosing and bridging on clinical outcomes in
patients with schizophrenia and schizoaffective disorder
who were switched from oral risperidone to paliperidone
LAI at VASDHS. The purpose of this study was to develop
dosing guidance for switching patients from oral risperi-
done to paliperidone LAI.
Methods
Study Design
This study was an Institutional Review Board–approved,
retrospective chart review involving patients at the
VASDHS. Patients were included if they were 18 years
or older, had a diagnosis of schizophrenia or schizoaffec-
tive disorder, were switched from oral risperidone to
paliperidone LAI at VASDHS between January 1, 2009,
and December 31, 2014, and received their paliperidone
injections at a VA facility. Patients were excluded if they
failed to meet inclusion criteria, had a creatinine clearance
50 mL/min, or were on a scheduled antipsychotic other
than paliperidone or risperidone (ie, antipsychotic poly-
pharmacy). Creatinine clearance was calculated using the
Cockcroft-Gault equation and adjusted body weight.
Baseline characteristics (demographic variables, medica-
tion history), psychiatric hospitalizations, emergency
department (ED) visits for a psychiatric complaint, mental
health (MH) urgent care visits, and number of scheduled
and attended MH appointments were collected via chart
review for 6 months prior to and after initiation of
paliperidone LAI. Only hospitalizations, ED/MH urgent
care visits, and MH appointments within the VA system
were included in the data.
Data Categorization: Optimal and
Suboptimal Dosing
Patients were categorized as optimal if they received
optimal loading doses and an optimal maintenance
dose. Optimal loading doses were based on recommen-
dations from the paliperidone LAI package insert.7
Optimal maintenance dose was based on the patient’s
last daily risperidone dose before the first paliperidone
injection and approximate equivalencies between oral
risperidone, paliperidone ER, and paliperidone LAI
found in the literature and package insert.7-9 For
patients with creatinine clearance 80 mL/min, optimal
loading doses were defined as paliperidone LAI 234 mg
intramuscularly (IM) on day 1, followed by paliperidone
LAI 156 mg IM between days 3 and 11. Maintenance
dose was classified as optimal if it was given between 2
and 6 weeks after the second loading dose and was
dosed based on oral risperidone dose: for patients on
3 mg/d, a maintenance dose of 117 mg; for patients
on 4 to 5 mg/d, a maintenance dose of 156 mg; for
patients on 6 mg/d, a maintenance dose of 234 mg.
For patients with creatinine clearance ,80 mL/min,
optimal loading doses were defined as paliperidone LAI
156 mg IM on day 1, followed by 1 dose of 117 mg IM
between days 3 and 11. Optimal maintenance dose was
defined as 78 mg of paliperidone LAI between 2 and 6
weeks after the second loading dose. All patients who
did not meet criteria for optimal dosing were catego-
rized as suboptimally dosed.
Data Categorization: Bridging
Only patients who were on risperidone doses 4 mg/d
prior to switching to paliperidone LAI were included in the
bridging arm, because these were patients at risk of
subtherapeutic levels from the recommended loading
doses.7-9 Patients were categorized as bridged if they
were continued on oral risperidone for 7 days past the
first dose of paliperidone LAI.
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Outcomes
The primary outcome was difference in reduction of
hospitalization days 6 months prior to and after initiation
of paliperidone LAI. Secondary outcomes were differences
in reduction of ED/MH urgent care visits and in percentage
of no-shows/cancellations to MH appointments. The
primary and secondary outcomes were compared for the
following groups: suboptimal and optimal (between
groups), bridged and not bridged (between groups), and
prepaliperidone and postpaliperidone (within group).
Statistical Analysis
An intent-to-treat analysis was conducted. Change in
hospitalization days, ED/MH urgent care visits, and
percentage of no-show/canceled MH appointments were
calculated using Microsoft Excel (Redmond, WA). Mann-
Whitney U tests for independent samples were used to
compare outcomes between the optimal and suboptimal,
and the bridged and not bridged groups. The Wilcoxon
signed rank test for paired samples was used to compare
outcomes 6 months prior to 6 months after the switch to
paliperidone LAI. Fisher exact t tests were used to detect
significant differences in baseline characteristics. All
statistical analyses were conducted using SPSS software
(Chicago, IL).
Results
Baseline Demographics
A total of 162 patients were identified who were initiated
on paliperidone LAI at the VASDHS between January 1,
2009, and December 31, 2014. Of the 162, a total of 75
met inclusion criteria. The most common reasons for
being excluded were having a diagnosis other than
schizophrenia/schizoaffective disorder (33) and being
switched from an antipsychotic other than risperidone
(31). Of the 75 included, 48 (64%) were classified as
suboptimal and 27 (36%) as optimal, and 55 were on 4
mg/d oral risperidone before switching to paliperidone
LAI. Of the 55 patients, 26 (47%) were bridged with 7
TABLE 1: Baseline demographics
All Suboptimal Optimal Not Bridged Bridged
No. (%) of patients 75 48 (64) 27 (36) . . . . . .
Risperidone 4 mg/d, No. (%) 55 (73.3) . . . . . . 29 (52.7) 26 (47.3)
Age, y, mean 48.5 50.5 44.9 47.3 50.9
Sex, No. (%)
Male 68 (90.7) 44 (91.7) 24 (88.9) 26 (89.7) 25 (96.2)
Female 7 (9.3) 4 (8.3) 3 (11.1) 3 (10.3) 1 (3.8)
Ethnicity, No. (%)
White 36 (48.0) 22 (45.8) 14 (51.9) 15 (51.7) 10 (38.4)
African American 26 (34.7) 18 (37.5) 8 (29.6) 11 (37.9) 11 (42.3)
Asian 5 (6.7) 3 (6.3) 2 (7.4) 0 (0) 2 (7.7)
Not specified 8 (10.7) 5 (10.4) 3 (11.1) 3 (10.3) 3 (11.5)
Diagnosis
Schizoaffective, No. (%) 26 (34.7) 13 (27.1) 13 (48.1) 13 (44.8) 6 (23.1)
Schizophrenia, No. (%) 49 (65.3) 35 (72.9) 14 (51.9) 16 (55.2) 20 (76.9)
CrCl, mL/min, mean 106 104 110 108 104
CrCl ,80 mL/min, No. (%) 10 (13.3) 8 (80) 2 (20) 3 (33.3) 6 (66.7)
CrCl 80 mL/min, No. (%) 65 (86.7) 40 (61.5) 25 (38.4) 26 (56.6) 20 (43.5)
Alcohol/drug dependence, No. (%)
Yes 36 (48.0) 21 (43.8) 15 (55.6) 14 (48.3) 10 (38.5)
No 39 (52.0) 27 (56.3) 12 (44.4) 15 (51.7) 16 (61.5)
Other psychiatric medications, No. (%)a
Yes 44 (58.7) 31 (64.6) 13 (48.1) 13 (44.8) 7 (26.9)
No 31 (41.3) 17 (35.4) 14 (51.9) 16 (61.5) 19 (73.1)
Oral risperidone dose, mean 4.8 5 4.5 5 6.4
Paliperidone LAI maintenance dose, mg, mean 114 77 181 93 147
CrCl¼ creatinine clearance; LAI ¼ long-acting injectable.
aOther psychiatric medications include antidepressants and mood stabilizers.
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days of oral risperidone and 29 (53%) were not. Table 1
summarizes the baseline characteristics of the comparator
groups. There were no statistically significant differences
in baseline characteristics between the suboptimal and
optimal, and the bridged and not bridged groups. The
most common reasons for suboptimal dosing were failure
to receive a maintenance dose (35%), followed by
receiving a suboptimal maintenance dose (25%), and
failure to receive a second loading dose (17%).
Optimal Versus Suboptimal Dosing
Table 2 summarizes the primary and secondary outcomes
for the optimal versus suboptimal and bridged versus not
bridged groups. There was no significant difference in
median reduction of days of hospitalization between the
optimal and suboptimal groups. The first and third
quartiles for reduction in hospitalization days were
numerically, but not statistically, greater in the suboptimal
group compared with the optimal group. The median, first
quartile, and third quartile for change in ED/MH urgent
care visits were approximately the same for suboptimal
and optimal groups. The first and third quartiles for
change in percentage of no-shows/cancellations to MH
appointments were numerically, but not statistically,
lower/more negative in the optimal group than in the
suboptimal group. The median change in percentage of
no-show/canceled MH visits was the same in the optimal
and suboptimal groups.
Bridged Versus Not Bridged
The dose of the risperidone bridge ranged from 2 to 12
mg/d and from 33% to 100% of the patient’s oral
risperidone dose, with a mode and median bridge dose
of 4 mg/d. The length of the risperidone bridge ranged
from 7 to 470 days, with a mode of 7 days and median of
29 days. The trimmed mean duration of bridging was 30
days. The median, first-quartile, and third-quartile reduc-
tions in hospitalization days were significantly greater in
patients who were bridged compared with those who
were not bridged. There were no significant differences in
the median, first quartile, and third quartile for reduction
of ED/MH urgent care visits between bridged and not
bridged groups. The first- and third-quartile reductions in
percentage of no-shows/cancellations to MH appoint-
ments were numerically, but not statistically, greater in
the bridged group compared with the not bridged group.
There was no difference in the median reduction of
percentage of no-showed/canceled MH appointments
between the bridged and not bridged groups.
Prepaliperidone LAI Versus
Postpaliperidone LAI
Table 3 summarizes the primary and secondary outcomes
6 months prior to and following the initiation of
paliperidone LAI. There were statistically significant
reductions in median, first-quartile, and third-quartile
hospitalization days and ED/MH urgent care visits in the
6 months after initiation of paliperidone LAI compared
with the 6 months prior to initiation. There was a
numerically, albeit not statistically significant, reduction
in median, first-quartile, and third-quartile percentage of
no-shows/cancellations to MH visits.
Discussion
Although there were some numeric trends favoring
patients who were optimally dosed, none of these reached
TABLE 2: Outcomes between suboptimal versus optimal and bridged versus not bridged groups
Suboptimal Optimal P Value Not Bridged Bridged P Value
Change in hospitalization daysa
First quartile 20.25 18
.787
14 31.5
.027*Median 11 8 8 17.5
Third quartile 0.75 0 8 1.5
Change in emergency department/mental health urgent care visitsa
First quartile 1 1.5
.397
2 1
.743Median 1 1 1 1
Third quartile 0 0 0 0
Change in percentage of no-showed/canceled mental health visitsa
First quartile 6.79 19.0
.311
6.78 22.2
.083Median 0 0 0 0
Third quartile 33.3 25 25 20
CrCl¼ creatinine clearance.
aPostpaliperidone value – prepaliperidone value.
*P, .05.
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statistical significance. This may in part be due to the
small sample size and the broad distribution of data. A
post hoc power analysis determined that, given the small
sample size, there was insufficient power to determine
statistical significance between the optimal and subopti-
mal groups. Additionally, the conversion from oral
risperidone to paliperidone LAI was based on reported
equivalencies in the literature and may require revision. It
is notable that the most prevalent reason (35%) for
patients receiving suboptimal dosing was a failure to
receive a maintenance dose injection. This indicates that
although LAI antipsychotics have been associated with
improved adherence compared with oral antipsychotics,
nonadherence to these medications can still occur and
should be addressed.
The results of this study suggest that bridging patients
who are on 4 mg/d risperidone with oral risperidone for
at least 7 days may be associated with a greater reduction
in hospitalization days. Since the recommended loading
doses result in levels approximately equivalent to 3 to 6
mg/d risperidone, bridging patients with oral risperidone
may help maintain therapeutic levels until the paliper-
idone LAI reaches steady state. There was a wide range of
bridging doses and durations. The most commonly used
bridging strategy was continuation of risperidone 4 mg/d
for 7 days after the first loading dose. However, further
research is required before a specific recommendation for
bridging can be made.
Switching from oral risperidone to paliperidone LAI was
associated with statistically significant decreases in
hospitalization days and ED/MH urgent care visits, even
though 64% of included patients were dosed subopti-
mally. This suggests that, even if the paliperidone LAI is
dosed suboptimally, switching patients from oral risperi-
done to paliperidone LAI may be associated with
decreased hospitalization days and ED/MH urgent care
visits. There was large variability in the dosing strategies
for loading, maintenance doses, and bridging, which
further illustrates the importance of a standardized dosing
protocol for transitioning patients from oral risperidone to
paliperidone LAI.
The primary limitations of this study were its retrospective
nature, small sample size, specific population (predomi-
nantly male and white), and restriction to VA data.
Additionally, outcomes were only assessed for 6 months
prior to and following initiation of paliperidone LAI. In
future studies, it may be beneficial to follow clinical
outcomes across a longer time period (eg, 1 year) and
across multiple health systems if possible.
Conclusion
This study suggested that bridging patients on risperidone
4 mg/d with at least 7 days of oral risperidone upon
initiation of paliperidone LAI is associated with greater
reduction in hospitalization days. Although there were no
significant differences between optimally and suboptimally
dosed patients, this study was also underpowered to detect
such a difference, given the small sample size. This study
also indicated that switching patients from oral risperidone
to paliperidone LAI is associated with significant reductions
in hospitalization days and visits to the ED/MH urgent care
clinics, regardless of whether patients were dosed optimally
or suboptimally. Given the retrospective nature of the study
and the large variability of dosing and bridging strategies,
further studies are warranted to determine the appropriate
dose conversion and bridging dose when switching from
oral risperidone to paliperidone LAI. As has been demon-
strated in previous studies, paliperidone LAI is associated
with improved clinical outcomes and remains a viable
option for patients who are nonadherent to oral medica-
tions. Given the increasing utility of LAI antipsychotics, it is
crucial to determine optimal dosing of these medications.
By doing so, we can use these medications effectively to
improve quality of life and clinical outcomes for our
psychiatric patients.
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